Literature DB >> 22561012

Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery.

Marc Miravitlles1, Juan José Soler-Cataluña, Myriam Calle, Jesús Molina, Pere Almagro, José Antonio Quintano, Juan Antonio Riesco, Juan Antonio Trigueros, Pascual Piñera, Adolfo Simón, José Luis López-Campos, Joan B Soriano, Julio Ancochea.   

Abstract

Recognizing the clinical heterogeneity of COPD suggests a specific therapeutic approach directed by the so-called clinical phenotypes of the disease. The Spanish COPD Guidelines (GesEPOC) is an initiative of SEPAR, which, together with the scientific societies involved in COPD patient care, and the Spanish Patient Forum, has developed these new clinical practice guidelines. This present article describes the severity classification and the pharmacological treatment of stable COPD. GesEPOC identifies four clinical phenotypes with differential treatment: non-exacerbator, mixed COPD-asthma, exacerbator with emphysema and exacerbator with chronic bronchitis. Pharmacological treatment of COPD is based on bronchodilation in addition to other drugs depending on the clinical phenotype and severity. Severity is established by the BODE/BODEx multidimensional scales. Severity can also be approximated by assessing airflow obstruction, dyspnea, level of physical activity and history of exacerbations. GesEPOC is a new, more individualized approach to COPD treatment according to the clinical characteristics of the patients.
Copyright © 2012 SEPAR. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22561012     DOI: 10.1016/j.arbres.2012.04.001

Source DB:  PubMed          Journal:  Arch Bronconeumol        ISSN: 0300-2896            Impact factor:   4.872


  66 in total

1.  Cost-Effectiveness of Fixed-Dose Combinations Therapies for Chronic Obstructive Pulmonary Disease Treatment.

Authors:  Margarita Capel; María Mareque; Carlos José Álvarez; Leandro Lindner; Itziar Oyagüez
Journal:  Clin Drug Investig       Date:  2018-07       Impact factor: 2.859

Review 2.  Molecular and biological pathways of skeletal muscle dysfunction in chronic obstructive pulmonary disease.

Authors:  Esther Barreiro; Joaquim Gea
Journal:  Chron Respir Dis       Date:  2016-04-06       Impact factor: 2.444

3.  Prognostic Indices and Mortality Prediction in COPD Caused by Biomass Smoke Exposure.

Authors:  Rafael Golpe; Noemí Mengual-Macenlle; Pilar Sanjuán-López; Esteban Cano-Jiménez; Olalla Castro-Añón; Luis A Pérez-de-Llano
Journal:  Lung       Date:  2015-04-30       Impact factor: 2.584

Review 4.  The asthma COPD overlap syndrome (ACOS).

Authors:  Stephen Bujarski; Amit D Parulekar; Amir Sharafkhaneh; Nicola A Hanania
Journal:  Curr Allergy Asthma Rep       Date:  2015-03       Impact factor: 4.806

5.  Exhaled nitric oxide predicts eosinophilic airway inflammation in COPD.

Authors:  Kun-Ta Chou; Kang-Cheng Su; Shiang-Fen Huang; Yi-Han Hsiao; Ching-Min Tseng; Vincent Yi-Fong Su; Shih-Chieh Hung; Diahn-Warng Perng
Journal:  Lung       Date:  2014-05-11       Impact factor: 2.584

6.  The effect of quitting smoking on costs and healthcare utilization in patients with chronic obstructive pulmonary disease: a comparison of current smokers versus ex-smokers in routine clinical practice.

Authors:  Antoni Sicras-Mainar; Javier Rejas-Gutiérrez; Ruth Navarro-Artieda; Jordi Ibáñez-Nolla
Journal:  Lung       Date:  2014-05-10       Impact factor: 2.584

Review 7.  The pharmacological approach to the elderly COPD patient.

Authors:  Timothy E Albertson; Michael Schivo; Amir A Zeki; Samuel Louie; Mark E Sutter; Mark Avdalovic; Andrew L Chan
Journal:  Drugs Aging       Date:  2013-07       Impact factor: 3.923

8.  Previous outpatient antibiotic use in patients admitted to hospital for COPD exacerbations: room for improvement.

Authors:  M Miravitlles; J J Soler-Cataluña; F Baranda; P Cordero; J-V Greses; C de la Roza
Journal:  Infection       Date:  2012-08-21       Impact factor: 3.553

9.  Factors associated with a low level of physical activity in patients with chronic obstructive pulmonary disease.

Authors:  Marc Miravitlles; Jordi Cantoni; Karlos Naberan
Journal:  Lung       Date:  2014-01-30       Impact factor: 2.584

10.  Clinical outcomes and cost analysis of exacerbations in chronic obstructive pulmonary disease.

Authors:  Marc Miravitlles; Cayo García-Polo; Adolfo Domenech; Gustavo Villegas; Francisco Conget; Cristian de la Roza
Journal:  Lung       Date:  2013-07-11       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.